Form 4: Dynavax CEO Ryan Spencer Reports Stock Transactions

CEO Ryan Spencer reports acquisition and disposal of Dynavax Technologies Corp stock and derivative securities.

Summary

• On February 13, 2025, Ryan Spencer, CEO and Director of Dynavax Technologies Corp, reported transactions involving the company's stock.
• Spencer acquired 62,500 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• He also disposed of 31,694 shares to satisfy tax withholding requirements related to the vesting of RSUs at a price of $12.69 per share.
• Additionally, Spencer was granted 225,000 stock options that vest over three years and 136,000 RSUs that vest over three years.
• Following these transactions, Spencer directly owns 242,261 shares of Dynavax common stock.
• He also holds 62,500 vested RSUs, 225,000 stock options, and 136,000 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of stock transactions by an executive. The vesting of RSUs is a positive, but the sale for tax obligations is a neutral event.

Positives

• The vesting of RSUs and granting of stock options to the CEO could be seen as a positive sign, aligning his interests with those of the shareholders.
• The vesting of RSUs indicates the achievement of certain performance conditions.

Negatives

• The disposal of shares to cover tax obligations, while standard, represents a reduction in the CEO's direct holdings.

Risks

• There are no specific risks mentioned in this document.
• However, insider transactions are always subject to scrutiny and could be perceived negatively if not properly understood.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is typical for executives receiving equity compensation.

Comparison to Industry Standards

• Equity compensation is a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
• Companies like Moderna, BioNTech, and Novavax also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and terms of these grants are generally comparable across the industry, with vesting periods typically ranging from three to four years.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, as they provide insight into the CEO's holdings and incentives.
• Employees participating in the ESPP may also be affected by the stock price.

Key Dates